Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (alliance)

Lawrence N. Shulman, Donald A. Berry, Constance T. Cirrincione, Heather P. Becker, Edith A. Perez, Ruth O'Regan, Silvana Martino, Charles L. Shapiro, Charles J. Schneider, Gretchen Kimmick, Harold J. Burstein, Larry Norton, Hyman Muss, Clifford A. Hudis, Eric P. Winer

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Fingerprint

Dive into the research topics of 'Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (alliance)'. Together they form a unique fingerprint.

Medicine & Life Sciences